NEW YORK, Dec. 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: [email protected] Phone: (646) 453-890 ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit claims are based on Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in Inspire stock. The case is pending in the U.S. District Court for the District of Minnesota [3]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," leading to a reduction in 2025 earnings per share guidance by over 80%. This was attributed to undisclosed factors affecting the rollout and weak demand due to excess inventory of older devices [7][8]. Stock Price Impact - Following the announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 5, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in this area [4]. - The firm has achieved significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [4]. Group 3: Case Background - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of misleading statements regarding the launch of its Inspire V device, which has faced significant setbacks and weak demand [2][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Inspire Medical to contact them to discuss their legal options [1]. - A federal securities class action has been filed against Inspire Medical, with a deadline of January 5, 2026, for investors to seek the role of lead plaintiff [2][7]. Group 2: Company Performance and Issues - Inspire Medical announced on August 4, 2025, that the launch of its Inspire V device was delayed due to treatment centers not completing necessary training and onboarding [5]. - The company faced billing and reimbursement challenges, as Medicare's approval of a CPT code for Inspire V did not coincide with the necessary software updates for claims processing [5]. - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [6]. Group 3: Market Impact - Following the announcement of setbacks, Inspire Medical's stock price plummeted over 32% in one day, from $129.95 to $87.91, resulting in a loss of approximately $1.2 billion in market capitalization [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, specifically titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - The lawsuit alleges that Inspire misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays and weak demand [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, attributing this to undisclosed factors including incomplete training at implanting centers and poor demand due to excess inventory of older devices [7]. - Following this announcement, Inspire's stock price fell by $42.04, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Points - Rosen Law Firm is reminding purchasers of Inspire Medical Systems, Inc. common stock about the lead plaintiff deadline of January 5, 2026, for a class action lawsuit [1] - Investors who purchased stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm [3] Company Details - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [5] - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]

Core Points - Class actions have been initiated on behalf of stockholders of Stride, Inc. and Inspire Medical Systems, Inc. with deadlines for lead plaintiff petitions approaching [1] Stride, Inc. (NYSE:LRN) - The class period for Stride, Inc. is from October 22, 2024, to October 28, 2025, with a lead plaintiff deadline of January 12, 2026 [5] - Allegations against Stride include inflating enrollment numbers, cutting staffing costs, ignoring compliance requirements, suppressing whistleblowers, and losing enrollments, leading to artificially inflated stock prices [5] Inspire Medical Systems, Inc. (NYSE:INSP) - The class period for Inspire Medical is from August 6, 2024, to August 4, 2025, with a lead plaintiff deadline of January 5, 2026 [5] - The lawsuit claims that the launch of Inspire V was unsuccessful due to poor demand and undisclosed challenges, resulting in a more than 80% reduction in 2025 earnings guidance and a stock price decline of over 32% [5]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to significant delays in adoption [5][6]. - The company faced weak demand for Inspire V as many customers had excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 to $87.91 between August 4 and August 5, 2025 [8].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to significant operational issues and a drastic reduction in earnings guidance following the announcement of delays in the launch of its new sleep apnea device, Inspire V [2][4]. Company Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V was delayed due to multiple issues, including inadequate training and onboarding of treatment centers, software update delays, and excess inventory leading to poor demand [2]. - The company reduced its 2025 earnings guidance by over 80%, from a range of $2.20 to $2.30 per share to a new range of $0.40 to $0.50 per share [2]. Stock Market Reaction - Following the announcement on August 5, 2025, Inspire's stock price dropped by $42.04, or 32.4%, closing at $87.91 per share, resulting in significant losses for investors [3]. Legal Allegations - The class action complaint alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [4]. - Specific allegations include poor demand for Inspire V due to surplus inventory, incomplete training for treatment centers, and failure to ensure necessary IT systems and Medicare reimbursement were in place at launch [4].

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...